Effect of Polymer Concentration and Surface Charge on Controllable Nanopesticides Delivery. [PDF]
Polymers (Basel)Cao R, Wu Y, Xu N, Zhang Y, Guo Z, Xu Y.
europepmc +1 more source
Co-Encapsulation of Curcumin and Fucoxanthin With Multilayer Structural Nanoparticles: In Vitro Programmed Sequential Release Behavior and In Vivo Bioavailability Studies. [PDF]
Food Sci NutrWang L, Wang M, Lv L, Xue C.
europepmc +1 more source
Gamma scintigraphic pulmonary deposition study of glycopyrronium/formoterol metered dose inhaler formulated using co-suspension delivery technology [PDF]
European Journal of Pharmaceutical Sciences, 2018 This gamma scintigraphy imaging study was the first to assess pulmonary and extrathoracic deposition and regional lung deposition patterns of a radiolabelled long-acting muscarinic antagonist/long-acting β2-agonist fixed-dose combination glycopyrronium/formoterol fumarate dihydrate (GFF) 14.4/10μg (equivalent to glycopyrrolate/formoterol fumarate 18/9 ...
Ubaldo J Martin, Omar Usmani
exaly +5 more sources
Pulmonary Pharmacology and Therapeutics, 2020 Budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI), formulated using co-suspension delivery technology, is a triple fixed-dose combination in late-stage clinical development for chronic obstructive pulmonary disease (COPD).We conducted two studies to characterize the pharmacokinetic (PK) profile of BGF MDI in patients with ...
Edward M Kerwin +2 more
exaly +3 more sources
Related searches:
This is the first study of the inhaled corticosteroid, budesonide, delivered by metered-dose inhaler (BD MDI) using innovative co-suspension delivery technology in adults with asthma.To characterize the effects of BD delivered by MDI on lung function and safety.Randomized, double-blind, 4-week cross-over, placebo-controlled, phase IIb study of adults ...
Earl St Rose +2 more
exaly +3 more sources
Co-suspension delivery technology in pressurized metered-dose inhalers for multi-drug dosing in the treatment of respiratory diseases [PDF]
Respiratory Medicine, 2018 Technologies for long-term delivery of aerosol medications in asthma and chronic obstructive pulmonary disease have improved over the past 2 decades with advancements in our understanding of the physical chemistry of aerosol formulations, device engineering, aerosol physics, and pulmonary biology.
Anthony J. Hickey, Gary T Ferguson
exaly +3 more sources
Drug Delivery from an Innovative LAMA/LABA Co-suspension Delivery Technology Fixed-Dose Combination MDI: Evidence of Consistency, Robustness, and Reliability [PDF]
AAPS PharmSciTech, 2017 To ensure consistency of clinical outcomes, orally inhaled therapies must exhibit consistent delivered dose and aerosol properties at the time of manufacturing, throughout storage, and during various patient-use conditions. Achieving consistency across these scenarios has presented a significant challenge, especially for combination products that ...
Amber, Doty +7 more
exaly +3 more sources
Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease [PDF]
Respiratory Medicine, 2017 The long-term safety and efficacy of a novel Co-Suspension™ Delivery Technology glycopyrrolate (GP)/formoterol fumarate (FF) 18/9.6 μg fixed-dose combination metered dose inhaler (GFF MDI) were investigated in a 28-week safety extension study (PINNACLE-3, NCT01970878) of two randomized controlled Phase III trials (PINNACLE-1 and -2; NCT01854645 and ...
Shahid Siddiqui +2 more
exaly +3 more sources
Pulmonary Pharmacology and Therapeutics, 2018 Chronic obstructive pulmonary disease (COPD) causes significant mortality in Japan. GFF MDI is a long-acting muscarinic antagonist/long-acting β2-agonist fixed-dose combination of glycopyrronium (GP) and formoterol fumarate dihydrate (FF), delivered by a metered dose inhaler (MDI) using co-suspension delivery technology, for the long-term maintenance ...
Shahid Siddiqui +2 more
exaly +3 more sources
PINNACLE-4 evaluated the efficacy and safety of the long-acting muscarinic antagonist/long-acting β2-agonist fixed-dose combination glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in patients from Asia, Europe, and the USA with moderate-to-very severe chronic obstructive pulmonary disease (COPD).
Yasuhiro, Gon +8 more
openaire +2 more sources